{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:02:16Z","timestamp":1793145736649,"version":"4.5.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Cell-free DNA (cfDNA) has emerged as a pivotal biomarker for predicting preeclampsia (PE), a multisystem syndrome characterized by placental hypoperfusion and systemic inflammation. This review synthesizes critical advances in the field, highlighting quantitative alterations in cfDNA, fragmentomic profiles, and placenta-specific methylation patterns (e.g., RASSF1A) that demonstrate significant value for early prediction and severity stratification of PE. Mechanistically, placental hypoxia-induced trophoblast apoptosis (releasing cfDNA), epigenetic dysregulation activating TLR9\/NF-\u03baB inflammatory pathways, and oxidative stress-mediated mitochondrial cfDNA fragmentation collectively drive disease progression. In clinical translation, integrating cfDNA with complementary biomarkers enhances predictive performance, though limitations persist regarding preanalytical variability and dynamic gestational changes. Future efforts must advance fragmentomics-integrated multi-omics frameworks for precision prediction, where assay standardization constitutes the fundamental translational bottleneck.<\/jats:p>","DOI":"10.3389\/fmed.2025.1539651","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T05:31:01Z","timestamp":1758259861000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Multidimensional roles of cfDNA fragmentomics in preeclampsia: from placental hypoxia and TLR9 inflammation to clinical risk stratification"],"prefix":"10.3389","volume":"12","author":[{"given":"Ziyi","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41572-023-00417-6","article-title":"Pre-eclampsia","volume":"9","author":"Dimitriadis","year":"2023","journal-title":"Nat Rev Dis Primers."},{"key":"B2","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S0140-6736(20)32335-7","article-title":"Pre-eclampsia","volume":"398","author":"Chappell","year":"2021","journal-title":"Lancet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12958-022-01003-3","article-title":"Diagnostic biomolecules and combination therapy for pre-eclampsia","volume":"20","author":"Qi","year":"2022","journal-title":"Reprod Biol Endocrinol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"103166","DOI":"10.1016\/j.critrevonc.2020.103166","article-title":"The main sources of circulating cell-free DNA: apoptosis, necrosis and active secretion","volume":"157","author":"Hu","year":"2021","journal-title":"Crit Rev Oncol Hematol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41581-021-00428-0","article-title":"Liquid biopsies: donor-derived cell-free DNA for the detection of kidney allograft injury","volume":"17","author":"Oellerich","year":"2021","journal-title":"Nat Rev Nephrol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e1011484","DOI":"10.1371\/journal.pgen.1011484","article-title":"Cell-free placental DNA: what do we really know?","volume":"20","author":"Yuen","year":"2024","journal-title":"PLoS Genet."},{"key":"B7","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1146\/annurev-biodatasci-020722-094144","article-title":"Noninvasive prenatal testing using circulating DNA and RNA: advances, challenges, and possibilities","volume":"6","author":"Moufarrej","year":"2023","journal-title":"Annu Rev Biomed Data Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"300.e1","DOI":"10.1016\/j.ajog.2023.03.026","article-title":"Obstetrical, perinatal, and genetic outcomes associated with nonreportable prenatal cell-free DNA screening results","volume":"229","author":"Norton","year":"2023","journal-title":"Am J Obstet Gynecol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1038\/s41591-023-02510-5","article-title":"Cell-free DNA methylome analysis for early preeclampsia prediction","volume":"29","author":"De Borre","year":"2023","journal-title":"Nat Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"19837","DOI":"10.1038\/s41598-022-24348-6","article-title":"Hypertensive disorders of pregnancy share common cfDNA methylation profiles","volume":"12","author":"Spinelli","year":"2022","journal-title":"Sci Rep."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1038\/s41440-023-01323-w","article-title":"Preeclampsia up to date\u2014What's going on?","volume":"46","author":"Bokuda","year":"2023","journal-title":"Hypertens Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1494072","DOI":"10.3389\/fcell.2024.1494072","article-title":"The role of DNA methylation in placental development and its implications for preeclampsia","volume":"12","author":"Meng","year":"2024","journal-title":"Front Cell Dev Biol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1527884","DOI":"10.3389\/fgene.2025.1527884","article-title":"Exploration of cfDNA landscape in NIPT and clinical utilities of cfDNA based gene expression inference in prenatal diagnostics","volume":"16","author":"Jia","year":"2025","journal-title":"Front Genet."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e2220982120","DOI":"10.1073\/pnas.2220982120","article-title":"Fragmentation landscape of cell-free DNA revealed by deconvolutional analysis of end motifs","volume":"120","author":"Zhou","year":"2023","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B15","doi-asserted-by":"publisher","first-page":"564","DOI":"10.3390\/ijms22020564","article-title":"Circulating total cell-free DNA levels are increased in hypertensive disorders of pregnancy and associated with prohypertensive factors and adverse clinical outcomes","volume":"22","author":"Amaral","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B16","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1080\/15592294.2020.1816774","article-title":"Cell-free DNA methylation and transcriptomic signature prediction of pregnancies with adverse outcomes","volume":"16","author":"Del Vecchio","year":"2021","journal-title":"Epigenetics."},{"key":"B17","doi-asserted-by":"publisher","first-page":"219","DOI":"10.18502\/jri.v24i4.14149","article-title":"Maternal and fetal factors affecting cell-free fetal DNA (cffDNA) fraction: a systematic review","volume":"24","author":"Zaki-Dizaji","year":"2023","journal-title":"J Reprod Infertil."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.3390\/diagnostics13152570","article-title":"Non-invasive prenatal testing (NIPT): reliability, challenges, and future directions","volume":"13","author":"Jayashankar","year":"2023","journal-title":"Diagnostics"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e021477","DOI":"10.1161\/JAHA.121.021477","article-title":"At preeclampsia diagnosis, total cell-free DNA concentration is elevated and correlates with disease severity","volume":"10","author":"Kolarova","year":"2021","journal-title":"J Am Heart Assoc."},{"key":"B20","doi-asserted-by":"publisher","first-page":"126.e1","DOI":"10.1016\/j.ajog.2021.01.020","article-title":"Prediction of preeclampsia throughout gestation with maternal characteristics and biophysical and biochemical markers: a longitudinal study","volume":"226","author":"Tarca","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"103780","DOI":"10.1016\/j.ebiom.2021.103780","article-title":"Clinical tools and biomarkers to predict preeclampsia","volume":"75","author":"MacDonald","year":"2022","journal-title":"EBioMedicine."},{"key":"B22","doi-asserted-by":"publisher","first-page":"100879","DOI":"10.1016\/j.gim.2023.100879","article-title":"Performance of prenatal cfDNA screening for sex chromosomes","volume":"25","author":"Martin","year":"2023","journal-title":"Genet Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/pd.6298","article-title":"A systematic review and meta-analysis of cell-free DNA testing for detection of fetal sex chromosome aneuploidy","volume":"43","author":"Shear","year":"2023","journal-title":"Prenat Diagn."},{"key":"B24","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1080\/10641955.2022.2066119","article-title":"Soluble endoglin versus sFlt-1\/PlGF ratio: detection of preeclampsia, HELLP syndrome, and FGR in a high-risk cohort","volume":"41","author":"Iannaccone","year":"2022","journal-title":"Hypertens Pregnancy."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preghy.2020.10.002","article-title":"Mitochondrial DNA copy number variation - a potential biomarker for early onset preeclampsia","volume":"23","author":"Pandey","year":"2021","journal-title":"Pregnancy Hypertens."},{"key":"B26","doi-asserted-by":"publisher","first-page":"176569","DOI":"10.1016\/j.ejphar.2024.176569","article-title":"Ghrelin alleviates placental dysfunction by down-regulating NF-\u03baB phosphorylation in LPS-induced rat model of preeclampsia","volume":"972","author":"Shen","year":"2024","journal-title":"Eur J Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.4110\/in.2018.18.e27","article-title":"Damage-associated molecular patterns in inflammatory diseases","volume":"18","author":"Roh","year":"2018","journal-title":"Immune Netw."},{"key":"B28","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1097\/PAI.0000000000001129","article-title":"Amalgamation of toll-like receptor and hypoxic signaling in etiology of preeclampsia","volume":"31","author":"Aggarwal","year":"2023","journal-title":"Appl Immunohistochem Mol Morphol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e13100","DOI":"10.1111\/aji.13100","article-title":"Toll-like receptor 9, maternal cell-free DNA and myometrial cell response to CpG oligodeoxynucleotide stimulation","volume":"81","author":"Beck","year":"2019","journal-title":"Am J Reprod Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1097\/HJH.0000000000003279","article-title":"Hydroxychloroquine reduces hypertension and soluble fms-like kinase-1 in a N\u03c9-nitro-l-arginine methyl ester-induced preeclampsia rat model","volume":"40","author":"Choi","year":"2022","journal-title":"J Hypertens."},{"key":"B31","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1089\/vim.2023.0044","article-title":"Effects of AIM2 and IFI16 on infectious diseases and inflammation","volume":"36","author":"Fan","year":"2023","journal-title":"Viral Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"431","DOI":"10.3390\/jcm12020431","article-title":"Predictive model for preeclampsia combining sFlt-1, PlGF, NT-proBNP, and uric acid as biomarkers","volume":"12","author":"Garrido-Gim\u00e9nez","year":"2023","journal-title":"J Clin Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"768","DOI":"10.3390\/ijerph20010768","article-title":"The association of IL-17 and PlGF\/sENG ratio in pre-eclampsia and adverse pregnancy outcomes","volume":"20","author":"Darmochwal-Kolarz","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"B34","doi-asserted-by":"publisher","first-page":"550.e1","DOI":"10.1016\/j.ajog.2024.03.012","article-title":"Angiogenic and vasoactive proteins in the maternal-fetal interface in healthy pregnancies and preeclampsia","volume":"231","author":"Westerberg","year":"2024","journal-title":"Am J Obstet Gynecol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.3390\/jcm13092668","article-title":"Understanding the pathophysiology of preeclampsia: exploring the role of antiphospholipid antibodies and future directions","volume":"13","author":"Mitranovici","year":"2024","journal-title":"J Clin Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e021726","DOI":"10.1161\/JAHA.121.021726","article-title":"Reduced maternal circulating cell-free mitochondrial DNA is associated with the development of preeclampsia","volume":"11","author":"Cushen","year":"2022","journal-title":"J Am Heart Assoc."},{"key":"B37","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.bpa.2022.03.003","article-title":"Maternal sepsis","volume":"36","author":"Filetici","year":"2022","journal-title":"Best Pract Res Clin anaesthesiol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.placenta.2023.10.008","article-title":"High placental expression of FLT1, LEP, PHYHIP and IL3RA - in persons of African ancestry with severe preeclampsia","volume":"144","author":"Aisagbonhi","year":"2023","journal-title":"Placenta."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e050963","DOI":"10.1136\/bmjopen-2021-050963","article-title":"Early-pregnancy prediction of risk for pre-eclampsia using maternal blood leptin\/ceramide ratio: discovery and confirmation","volume":"11","author":"Huang","year":"2021","journal-title":"BMJ Open."},{"key":"B40","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.healun.2021.03.007","article-title":"Cell-free DNA beyond a biomarker for rejection: biological trigger of tissue injury and potential therapeutics","volume":"40","author":"Tsuji","year":"2021","journal-title":"J Heart Lung Transpl."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1539651\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T05:31:03Z","timestamp":1758259863000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1539651\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":40,"alternative-id":["10.3389\/fmed.2025.1539651"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1539651","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]},"article-number":"1539651"}}